Erincy and her husband Stephen hug children Avery 6 and Aidan 11, after receiving the second Moderna COVID-19 vaccine at Kaiser Permanente Los Angeles Medical Center on Friday, June 25, 2021.
Sarah Reingwirtz | media newsgroups | Getty Images
Moderna said on Monday that a low dose of the Covid-19 vaccine is safe and produced a strong immune response in a study of children aged 6 to 11.
In a press release, the company cited preliminary data from a phase 2/3 trial, where two doses of 50 micrograms of the vaccine are half the dose given to adults, with an antibody level of 1.5 detected in young adults. He said that double antibody level was obtained.
According to the company, the shot was generally well tolerated in young children, with the most common side effects being fatigue, headache, fever and pain at the injection site. The vaccine has been tested on more than 4,700 children.
Moderna said it plans to submit the data “in the short term” to the Food and Drug Administration, the European Medicines Agency and other health regulators.
In a statement, Modana CEO Stephen Bansel said, “We look forward to filing with regulators around the world to end the COVID-19 pandemic with vaccines for adults and children of all ages. I promise to do my best. “
The new data comes a day ahead of a key FDA advisory board meeting to discuss whether to recommend Pfizer and BioNTech vaccines to 5-11-year-olds. The FDA could approve the shot within days of the meeting, and the Centers for Disease Control and Prevention will approve it as early as next week.
FDA employees said late Friday that the Pfizer vaccine appears to be very effective in preventing sexually transmitted infections in elementary school children.
Many parents say they want their children to be vaccinated when a new school year begins. According to the American Academy of Pediatrics, the number of new covid cases in children is very high, which has involved more than 1.1 million children in the past six weeks.
Moderna says the COVID vaccine produces a stronger immune response in 6 to 11-year-olds
Source link Moderna says Covid vaccine produces a stronger immune response in children aged 6 to 11